LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

Published on Dec 1, 2019in Annals of Oncology32.976
· DOI :10.1093/ANNONC/MDZ453.001
Byoung Chul Cho65
Estimated H-index: 65
 (Yonsei University)
Sources
Abstract
Abstract Background Somatic KRAS mutations are detected in approximately 15%-30% of lung adenocarcinomas, with regional variation, and are associated with poor prognosis. We explored the prevalence of KRAS mutations and their association with efficacy in participants (pts) with non-squamous NSCLC enrolled in the KEYNOTE-042 study of pembrolizumab monotherapy vs platinum-based chemotherapy as first-line therapy for advanced PD-L1-positive (TPS ≥1%) NSCLC (NCT02220894). Methods KRAS mutational status and tumor mutational burden (TMB) were assessed by whole-exome sequencing (WES) in pts with who had available tumor and matched-normal tissue. This exploratory analysis included descriptive analyses of the correlation between KRAS mutational status and shifts in distributions of TMB and PD-L1 expression and the association of KRAS and KRAS G12C status with efficacy. Results Of the 782 pts with non-squamous histology, 301 (38%) were evaluable by WES and had matched tumor and normal DNA. KRAS mutations were identified in 69 (23%) pts, including 29 (10%) G12C carriers. Pts with vs without KRAS mutation tended to have higher PD-L1 TPS (median [IQR] 60% [10-95] vs 35% [10-80]) and TMB (median [IQR] 191 [129-288] vs 105 [56-226] mut/exome). Outcomes of pembrolizumab and of chemotherapy for pts with and without KRAS mutation and for KRAS G12C carriers are in the table. Of note, CIs were wide given the modest frequency of KRAS mutation and low frequency of KRAS G12C.TableLBA4TableWith Any KRAS MutationWith KRAS G12C MutationWithout Any KRAS MutationPembro Mono-therapy (N = 30)Chemo-therapy (N = 39)Pembro Mono-therapy (N = 12)Chemo-therapy (N = 17)Pembro Mono-therapy (N = 127)Chemo-therapy (N = 105)ORR, % (95% CI)56.7 (37.4-74.5)18.0 (7.5-33.5)66.7 (34.9-90.1)23.5 (6.8-49.9)29.1 (21.4-37.9)21.0 (13.6-30.0)PFS, median, mo (95% CI)12 (8-NR)6 (4-9)15 (10-NR)6 (4-8)6 (4-7)6 (6-8)PFS, HR (95% CI)0.51 (0.29-0.87)0.27 (0.10-0.71)1.00 (0.75-1.34)OS, median, mo (95% CI)28 (23-NR)11 (7-25)NR (23-NR)8 (5-NR)15 (12-24)12 (11-18)OS, HR (95% CI)0.42 (0.22-0.81)0.28 (0.09-0.86)0.86 (0.63-1.18) Conclusion Findings of this descriptive exploratory analysis suggest that pembrolizumab monotherapy should be considered as a standard first-line treatment option for PD-L1-positive advanced non-squamous NSCLC regardless of KRAS mutational status. These findings also suggest that a pembrolizumab-containing regimen is a clinically relevant comparator for studies of KRAS -targeted therapy given as first-line treatment of NSCLC. Clinical trial identification KEYNOTE-042; NCT02220894. Editorial acknowledgement Joanne Tomassini and Melanie Leiby, both of Merck & Co., Inc., Kenilworth, NJ, for writing support. Legal entity responsible for the study Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Disclosure R.S. Herbst: Advisory / Consultancy: Abbvie Pharmaceuticals; Advisory / Consultancy: ARMO Biosciences; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Biodesix; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (self): Eli Lilly and Company; Advisory / Consultancy: EMD Serrano; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Genmab; Advisory / Consultancy: Halozyme; Advisory / Consultancy: Heat Biologics; Advisory / Consultancy: Infinity Pharmaceuticals; Advisory / Consultancy: Loxo Oncology; Advisory / Consultancy, Research grant / Funding (self): Merck & Co., Inc., Kenilworth, NJ, USA; Advisory / Consultancy: Nektar; Advisory / Consultancy: Neon Therapeutics; Advisory / Consultancy: NextCure; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Shire PLC; Advisory / Consultancy: Spectrum Pharmaceuticals; Advisory / Consultancy: Symphogen; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Tocagen; Officer / Board of Directors: Junshi Pharmaceuticals. G. Lopes: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): EMD Serono; Research grant / Funding (institution): Merck & Co., Inc.. D.M. Kowalski: Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy: Boehringer-Ingelheim; Advisory / Consultancy: Roche; Advisory / Consultancy: Pfizer; Advisory / Consultancy: BMS. K. Kasahara: Research grant / Funding (institution): MSD. Y-L. Wu: Advisory / Consultancy, Research grant / Funding (institution): Boehringer-Ingelheim; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): MSD; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self): Eli Lilly; Honoraria (self): Pierre Fabre; Honoraria (self): Pfizer; Honoraria (self): Sanofi. G. De Castro Jr.: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck Serono; Honoraria (self), Honoraria (institution), Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Boehringer-Ingelheim; Honoraria (self), Honoraria (institution): Novartis; Honoraria (institution): Amgen; Honoraria (institution): Astellas. B.C. Cho: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Roche; Speaker Bureau / Expert testimony: Bristol Myers Squibb; Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Yuhan. H.Z. Turna: Research grant / Funding (institution): MSD. R. Cristescu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme. D. Aurora-Garg: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme. J. Lunceford: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme. J. Kobie: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme. M. Ayers: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme. M.C. Pietanza: Shareholder / Stockholder / Stock options, Non-remunerated activity/ies: Merck Sharp & Dohme. B. Piperdi: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme. T.S.K. Mok: Honoraria (self), Advisory / Consultancy, Leadership role, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Clovis Oncology; Research grant / Funding (institution): Eisai; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): SFJ Pharmaceuticals; Research grant / Funding (institution): Taiho; Research grant / Funding (institution): Xcovery; Honoraria (self), Advisory / Consultancy: Roche/Genentech; Honoraria (self), Leadership role, Shareholder / Stockholder / Stock options: Hutchinson MedPharma; Honoraria (self): Janssen; Honoraria (self): Takeda; Honoraria (self): Fishawack Facilitate Ltd; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: ACEA Biosciences Inc.; Advisory / Consultancy: Celgene, Vertex, geneDecode, OncoGenex, Ignyta; Leadership role, Shareholder / Stockholder / Stock options: Sanomics Ltd; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Cirina; Non-remunerated activity/ies, ASCO board of directors: ASCO; Non-remunerated activity/ies, track chair for ESMO 2019: ESMO.
📖 Papers frequently viewed together
201932.98Annals of Oncology
18 Authors (Martin Reck)
201932.98Annals of Oncology
13 Authors (Keiichi Fujiwara, ..., Krishnansu S. Tewari)
201932.98Annals of Oncology
18 Authors (R. de Wit, ..., Arjun Vasant Balar)
References0
Newest
Cited By22
Newest
Abstract null Introduction null Abemaciclib is an oral, selective small-molecule cyclin-dependent kinase 4 and 6 inhibitor. In preclinical models, abemaciclib synergized with PD-1 blockade to enhance antitumor efficacy. Here, we report the safety and anticancer activity of abemaciclib plus pembrolizumab in 2 cohorts with non-small cell lung cancer (NSCLC). null Methods null This nonrandomized, open-label, phase 1b study included patients with previously untreated PD-L1-positive, KRAS-mutant non-...
Source
Dec 1, 2021·Critical Reviews in Oncology Hematology6.31
#1Nabih Naim (""St. Joe's"": Saint Joseph's University)
#2Sara Moukheiber (""St. Joe's"": Saint Joseph's University)
Last. Hampig Raphael Kourie (""St. Joe's"": Saint Joseph's University)H-Index: 18
view all 4 authors...
Abstract null null RAS is the most frequently mutated oncogene in human cancer. Scientists attempted for decades to target this protein or its pathways, however, all the attempts failed and RAS was labeled as “undruggable”. With KRAS-G12C covalent inhibitors entering clinical trials, the myth of this “undruggable” RAS is fading away. In 2021, the Food and Drug Administration (FDA) approved the use of Sotorasib (Lumakras) for the treatment of adult patients with KRAS-G12C mutated locally advanced...
Source
Dec 31, 2021·European Respiratory Review8.84
#1Jordi RemonH-Index: 27
#2Francesco Facchinetti (Institut Gustave Roussy)H-Index: 22
Last. Benjamin Besse (Université Paris-Saclay)H-Index: 75
view all 3 authors...
The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small cell lung cancer (NSCLC), ICIs have shifted treatment paradigm and improved overall survival reaching almost one-third of patients alive at 5 years. ICIs therapies have also modified the therapeutic strategy in first-line setting in metastatic small-cell lung cancer (SCLC) patients as well as in malignant pleural mesoth...
Source
PURPOSE The most frequent mutation in advanced non-small-cell lung cancer (NSCLC), Kirsten rat-sarcoma viral oncogene (KRAS) is found in 20-25% of these patients' tumors. While phase III trials on therapies targeting KRAS, especially KRASG12C, are ongoing, the clinical efficacy of anti-programmed death protein-1 (PD-1) or its ligand (PD-L1) against KRAS-mutant NSCLCs remains a topic of debate. METHODS This meta-analysis examined randomized-trial data comparing first- or second-line anti-PD-(L)1 ...
Source
Jul 16, 2021·Lung Cancer5.71
#1Colin R Lindsay (University of Manchester)H-Index: 18
#2M.C. Garassino (U of C: University of Chicago)H-Index: 12
Last. Julien MazieresH-Index: 74
view all 6 authors...
Abstract null null Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered ‘undruggable’, several novel direct KRASG12C inhibitors have shown encouraging signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by the US Food and Drug Administration. This review examines the ro...
Source
Jun 11, 2021·Immunotherapy4.20
#1Alexander P DavisH-Index: 2
#2Wendy A Cooper (RPA: Royal Prince Alfred Hospital)H-Index: 36
Last. Steven Kao (USYD: University of Sydney)H-Index: 30
view all 6 authors...
KRAS-mutant non-small-cell lung cancer is the most common molecular driver of lung adenocarcinoma in western populations. No KRAS specific therapy has been approved by the FDA until 2021. Despite significant heterogeneity in comutations, patients typically receive single-agent immunotherapy or chemoimmunotherapy as standard first-line therapy. It is unclear whether KRAS mutations predict outcomes with immunotherapy; however, there is emerging data suggesting improved outcomes in patients with a ...
Source
Jun 2, 2021·Annals of Oncology32.98
#1Martin ReckH-Index: 86
#3M.C. Garassino (U of C: University of Chicago)H-Index: 12
Abstract null null Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS accounts for 85% of RAS mutations observed in human cancers and is present in 35% of lung adenocarcinomas. While the use of targeted therapies and immune checkpoint inhibitors (CPIs) has drastically changed the treatment landscape of advanced non–small cell lung cancer (NSCLC) in recent years, historic attempts to...
Source
ABSTRACT Introduction KRAS mutations, the most frequent gain-of-function alterations in non-small cell lung cancer (NSCLC), are currently emerging as potential predictive therapeutic targets. KRAS-G12C (Kr_G12C) role is of special interest, following the recent discovery and preclinical analyses of two different Kr_G12C covalent inhibitors (AMG-510, MRTX849). Methods KRAS mutations were assessed in FFPE tissue sections by a microfluidics-based multiplex PCR platform as a component of the previou...
Source
Jun 1, 2021·JAMA Oncology31.78
#1Lova Sun (UPenn: University of Pennsylvania)H-Index: 12
#3Roger B. Cohen (UPenn: University of Pennsylvania)H-Index: 35
Last. Charu Aggarwal (UPenn: University of Pennsylvania)H-Index: 29
view all 6 authors...
Source
May 4, 2021·Pharmaceutics6.32
#1Alice IndiniH-Index: 14
#2Erika RijavecH-Index: 21
Last. Francesco Grossi (University of Insubria)H-Index: 7
view all 5 authors...
Activating mutations in RAS family proteins are found in ~25% of all human cancers. Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten RAS (KRAS) being the most frequently mutated isoform. Historically, KRAS has been acknowledged as “undruggable”, largely because the RAS proteins do not appear to present suitable pockets to which small inhibitory molecules can bind. However, this scenario has changed over the last years with the advent of novel KRAS inh...
Source
123
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.